Want to see HK:8189 full AI Analyst Report?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) Price & Analysis

2 Followers

8189 Stock Chart & Stats

HK$0.40

HK$0.00(0.00%)

At close: Jan 09 4:00 PM EST

HK$0.40

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.11 - HK$0.49

Previous CloseN/A

Volume305.00K

Average Volume (3M)1.41M

Market Cap

HK$576.29M

Enterprise ValueHK$729.98

Total Cash (Recent Filing)HK$29.22M

Total Debt (Recent Filing)HK$109.79M

Price to Earnings (P/E)―

Beta0.22

Next Earnings

Apr 01, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding1,436,400,000

10 Day Avg. Volume824,500

30 Day Avg. Volume1,413,333

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)46.59

Price to Sales (P/S)1.12

P/FCF Ratio-9.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Top-line ReboundA 125% revenue rebound in 2025 provides a materially larger revenue base to absorb fixed costs and invest in operations. If sustained, this improves the company's ability to scale core activities, support product development or distribution, and creates optionality to pursue margin recovery over the next several quarters.

Trailing Revenue GrowthA multi-period revenue growth rate near 36% signals persistent demand recovery beyond a single-year rebound. Durable top-line growth helps justify ongoing investment, supports longer-term planning, and increases the potential to leverage fixed-cost base to drive eventual operating leverage if cost control improves.

Low Historical BetaA low beta indicates lower correlation with broad market swings, suggesting earnings and cash flows may be less cyclically volatile. For long-term investors and creditors this can translate into more predictable operating outcomes and a clearer runway for restructuring or strategic initiatives over a 2–6 month horizon.

Bears Say

Very High LeverageDebt-to-equity near 9x represents extreme leverage and materially reduced financial flexibility. High leverage increases refinancing and covenant risk if losses persist, constrains capital allocation, and elevates the probability that additional external funding or asset disposals will be required to sustain operations.

Consistent Negative Cash GenerationSustained negative operating and free cash flow over multiple years indicates the core business is not self-funding. This forces reliance on external financing, raises dilution or solvency risk, and limits the firm’s ability to invest in capex, R&D, or working capital without worsening leverage or incurring high funding costs.

Weak, Volatile Margins And LossesVery low gross margins and persistent operating and net losses point to structural cost or pricing issues. Even with rising revenue, the inability to convert sales into sustainable profits undermines long-term viability and suggests significant margin improvement or business-model changes are required to reach durable profitability.

8189 FAQ

What was Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price range in the past 12 months?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H lowest stock price was HK$0.11 and its highest was HK$0.48 in the past 12 months.

What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap is HK$576.29M.

When is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s upcoming earnings report date?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 228 days.

How were Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s earnings last quarter?

Currently, no data Available

Is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H overvalued?

According to Wall Street analysts Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H pay dividends?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H does not currently pay dividends.

What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H have?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1,436,400,000 shares outstanding.

What happened to Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Tianjin TEDA Biomedical Engineering Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8189

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-16.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

Tianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based in Tianjin, People's Republic of China, is a diversified enterprise primarily involved in the research, development, manufacturing, and distribution of biological compound fertilizer products throughout the PRC. Its operations are organized into two main divisions: Biological Compound Fertilizers and Elderly and Health Care Services. The company's agricultural offerings encompass active fertilizers and various tailored blends of nitrogen, phosphorus, and potassium, specifically formulated to promote balanced growth for a range of crops including grains, fruits, and vegetables. Beyond agriculture, Tianjin TEDA Biomedical provides integrated care for the elderly and comprehensive health services. This includes leasing essential equipment for seniors and offering specialized consulting, advisory, and assessment solutions. Furthermore, the company develops and licenses electroencephalography (EEG) diagnosis detection services, utilizing its expertise in EEG technology for diagnostic applications. Its extensive activities also cover the research, development, production, and practical application of biomedical science and technology projects, alongside regional soil resource conditioning and remediation, and the provision of soil environmental quality standards research services.